menu
    • menu

    Company profile for Novus Therapeutics, Inc

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Novus Therapeutics is made from passionate people driven by a common vision to solve unmet clinical needs for patients in an underserved therapeutic area. Our product development experience and industry expertise provide the foundation for nimble and creative approaches to bringing new therapies to market. We aspire to deliver novel or significantly improved treatment options to patients in need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novus Therapeutics, IncUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    19900 MacArthur Blvd., Suite 550 Irvine, California 92612, USA
    Telephone
    Telephone
    +1 949-238-8090
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://novustherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/novustherapeutics/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/NovusThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novus Announces Name Change to Eledon Pharmaceuticals; Provides
    Novus Announces Name Change to Eledon Pharmaceuticals; Provides

    04 Jan 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/01/04/2152618/0/en/Novus-Therapeutics-Announces-Name-Change-to-Eledon-Pharmaceuticals-Provides-Corporate-Update-and-Outlook.html#:~:text=In%20connection%20with%20the%20name,at%20www.eledon.com.&text=The%20number%20of%20outstanding%20shares,affected%20by%20the%20name%20change.

    GLOBENEWSWIRE
    04 Jan 2021
    Share Share
    Novus Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L
    Novus Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L

    02 Nov 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201102005283/en

    BUSINESSWIRE
    02 Nov 2020
    Share Share
    Novus Announces First Patient Enrolled in Ph 2a Clinical Trial of Anti-CD40L
    Novus Announces First Patient Enrolled in Ph 2a Clinical Trial of Anti-CD40L

    02 Nov 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/novus-therapeutics-announces-first-patient-enrolled-in-phase-2a-clinical-trial-of-anti-cd40l-antibody-at-1501-in-amyotrophic-lateral-sclerosis/

    BIOSPACE
    02 Nov 2020
    Share Share
    Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
    Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

    02 Oct 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201002005351/en

    BUSINESSWIRE
    02 Oct 2020
    Share Share
    Novus Therapeutics announces 1-for-18 reverse stock split
    Novus Therapeutics announces 1-for-18 reverse stock split

    02 Oct 2020

    // Akansha Bakshi SEEKINGALFA

    https://seekingalpha.com/news/3619440-novus-therapeutics-announces-1-forminus-18-reverse-stock-split

    Akansha Bakshi SEEKINGALFA
    02 Oct 2020
    Share Share
    Novus Finalizes Acquisition of Anelixis to Further Develop AT-1501
    Novus Finalizes Acquisition of Anelixis to Further Develop AT-1501

    16 Sep 2020

    // BIOSPACE

    https://www.biospace.com/article/novus-finalizes-acquisition-of-anelixis-to-further-develop-at-1501/?s=79

    BIOSPACE
    16 Sep 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search